MAY 11, 2017 6:20 AM PDT

First ALS Drug Approved in Over 2 Decades

WRITTEN BY: Xuan Pham

For the first time in over 20 years, the US Food and Drug Administration approved a new drug for the treatment of a disease commonly known as Lou Gehrig’s disease.

Known formally as amyotrophic lateral sclerosis (ALS), Lou Gehrig's disease is a fatal condition caused by the gradual breakdown and death of motor neurons in the spinal cord. All muscles under voluntary control are affected, causing muscle weakness and severe impairments in daily functions. There is no known cure and most ALS patients die from respiratory failure within 3 to 5 years from the onset of symptoms.

The new drug is known as Radicava or edaravone, and it was developed by Japanese Mitsubishi Tanabe Pharma. Trials for the drug conducted in Japan showed the drug slowed the progression of the disease. The 2015 phase 3 data from a six-month placebo-controlled study found the drug contributed to a 33 percent reduction in physical decline in ALS patients. So while the drug can’t reverse the trajectory of ALS, it could give patients just a little more time and freedom.

Interestingly, the FDA’s approval of the drug was based solely on data collected from the Japanese trial. These results were so compelling that the FDA worked with the company to file for US approval.

“After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

Radicava is administered intravenously, with each infusion estimated to cost $1,086, and a year’s treatment costing $145,524 without assistance.

Prior to radicava, the 12-15,000 ALS patients had access to only one other approved ALS drug, riluzole by Sanofi. Riluzole was approved for ALS in 1995. Similar to radicava, the drug slows the progression of the disease, delaying the onset of ventilator-dependence and tracheotomy in some patients. The drug is estimated to prolong survival by two to three months.

For ALS patients and advocates, the approval of radicava marks a significant milestone. "We thank the FDA and MT Pharma for working together to expedite the approval of the first new ALS-specific treatment in decades," said ALS Association President Barbara Newhouse. "We hope (the) announcement signals the beginning of a new chapter in the fight against this terrible disease." The new drug is expected to come on the US market in August 2017.

Additional source: CNN

Image credit: pixabay.com

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 17, 2020
Coronavirus
A Biomarker May Predict the Most Severe COVID-19 Cases
SEP 17, 2020
A Biomarker May Predict the Most Severe COVID-19 Cases
Researchers may have found a way to identify the COVID-19 patients that will need targeted therapies the most.
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
OCT 01, 2020
Clinical & Molecular DX
Presenting the World's Smallest Ultrasound Detector
OCT 01, 2020
Presenting the World's Smallest Ultrasound Detector
It’s smaller than a human cell, but the diminutive size of the newly-developed ultrasound detector is by no means ...
DEC 02, 2020
Clinical & Molecular DX
Digital Platform Watches for a Silent COVID Killer
DEC 02, 2020
Digital Platform Watches for a Silent COVID Killer
 
DEC 31, 2020
Clinical & Molecular DX
Silent Mice Drive Autism Gene Discovery
DEC 31, 2020
Silent Mice Drive Autism Gene Discovery
Around 1 in 54 children in the U.S. are diagnosed with autism spectrum disorder, or ASD, a broad range of conditions tha ...
DEC 30, 2020
Neuroscience
Brain Imaging Predicts Risk of PTSD
DEC 30, 2020
Brain Imaging Predicts Risk of PTSD
Until now, why posttraumatic stress disorder (PTSD) develops in some and not others following a physical and/ or psychol ...
Loading Comments...